TrialThe Lancet. Haematology2023

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.

Emmanuela E Ambrose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.